Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Blue Ridge institute for medical research in horse shoe. www.brimr.org/PKI/PKIs.htm
  Google Scholar
• 2  Sartore-Bianchi A, Ricotta R, Cerea G, Maugeri MR, Siena S. Rationale and clinical results of multi-target treatments in oncology. Int. J. Biol. Markers22(1 Suppl. 4),S77–S87 (2007).
  Medline CASGoogle Scholar
• 3  Rauch J, Volinsky N, Romano D, Kolch W. The secret life of kinases: functions beyond catalysis. Cell Commun. Signal.9(1),23 (2011).
  Medline CASGoogle Scholar
• 4  Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science298(5600),1912–1934 (2002).▪ Highly cited reference in which the human kinome is defined.
  Medline CASGoogle Scholar
• 5  The human kinome online. http://kinase.com/kinbase
  Google Scholar
• 6  Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res.62(15),4236–4243 (2002).
  Medline CASGoogle Scholar
• 7  Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell7(2),129–141 (2005).
  Medline CASGoogle Scholar
• 8  Manley PW, Cowan-Jacob SW, Buchdunger E et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer38(Suppl. 5),S19–S27 (2002).
  MedlineGoogle Scholar
• 9  Davis MI, Hunt JP, Herrgard S et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol.29(11),1046–1051 (2011).▪▪ One of the first large scale evaluations of kinase selectivity.
  Medline CASGoogle Scholar
• 10  Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov.5(10),835–844 (2006).
  Medline CASGoogle Scholar
• 11  Taipale M, Krykbaeva I, Whitesell L et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol.31,630–637 (2013).
  Medline CASGoogle Scholar
• 12  Tao ZF, Wang L, Stewart KD et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J. Med. Chem.50(7),1514–1527 (2007).
  Medline CASGoogle Scholar
• 13  Liu Q, Sabnis Y, Zhao Z et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol.20(2),146–159 (2013).
  MedlineGoogle Scholar
• 14  Meggers E, Atilla-Gokcumen GE, Bregman H et al. Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. SYNLETT8,1177–1189 (2007).
  Google Scholar
• 15  Zuccotto F, Ardini E, Casale E, Angiolini M. Through the ‘gatekeeper door’: exploiting the active kinase conformation. J. Med. Chem.53(7),2681–2694 (2010).
  Medline CASGoogle Scholar
• 16  Hill ZB, Perera BG, Andrews SS, Maly DJ. Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. ACS Chem. Biol.7(3),487–495 (2012).
  Medline CASGoogle Scholar
• 17  Tomita N, Hayashi Y, Suzuki S et al. Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg. Med. Chem. Lett.23(6),1779–1785 (2013).
  Medline CASGoogle Scholar
• 18  Heinrich T, Graedler U, Boettcher H, Blaukat A, Shutes A. Allosteric IGF-1R inhibitors. ACS Med. Chem. Lett.1,199–203 (2010).
  Medline CASGoogle Scholar
• 19  Getlik M, Simard JR, Termathe M et al. Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38alpha kinase. PLoS ONE7(7),e39713 (2012).
  Medline CASGoogle Scholar
• 20  Uitdehaag JC, Verkaar F, Alwan H, De Man J, Buijsman RC, Zaman GJ. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol.166(3),858–876 (2012).
  Medline CASGoogle Scholar
• 21  Fang ZZ, Grutter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem. Biol.8(1),58–70 (2013).
  Medline CASGoogle Scholar
• 22  Adrian FJ, Ding Q, Sim T et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol.2(2),95–102 (2006).▪ Discovery of highly potent and selective allosteric inhibitors of ABL kinase.
  Medline CASGoogle Scholar
• 23  Zhang J, Adrian FJ, Jahnke W et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature463(7280),501–506 (2010).
  Medline CASGoogle Scholar
• 24  Iwatani M, Iwata H, Okabe A et al. Discovery and characterization of novel allosteric FAK inhibitors. Eur. J. Med. Chem.61,49–60 (2013).
  Medline CASGoogle Scholar
• 25  Vanderpool D, Johnson TO, Ping C et al. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry48(41),9823–9830 (2009).
  Medline CASGoogle Scholar
• 26  Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol. Cancer Ther.8(9),2559–2565 (2009).
  Medline CASGoogle Scholar
• 27  Deacon SW, Beeser A, Fukui JA et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol.15(4),322–331 (2008).
  Medline CASGoogle Scholar
• 28  Lindsley CW, Zhao Z, Leister WH et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett.15(3),761–764 (2005).
  Medline CASGoogle Scholar
• 29  Lindvall M, Karpov A, Bellamacina C et al. Discovery of novel and highly selective allosteric inhibitors of PAK1. Presented at: 246th ACS National Meeting and Exposition. IN, USA, 8–12 September 2013.
  Google Scholar
• 30  Iwata H, Oki H, Okada K et al. A back-to-front fragment-based drug design search strategy targeting the DFG-out pocket of protein tyrosine kinases. ACS Med. Chem. Lett.3,342–346 (2012).
  Medline CASGoogle Scholar
• 31  Pargellis C, Tong L, Churchill L et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol.9(4),268–272 (2002).
  Medline CASGoogle Scholar
• 32  Ohren JF, Chen H, Pavlovsky A et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol.11(12),1192–1197 (2004).
  Medline CASGoogle Scholar
• 33  Simard JR, Kluter S, Grutter C et al. A new screening assay for allosteric inhibitors of cSrc. Nat. Chem. Biol.5(6),394–396 (2009).
  Medline CASGoogle Scholar
• 34  Schneider R, Becker C, Simard JR et al. Direct binding assay for the detection of type IV allosteric inhibitors of Abl. J. Am. Chem. Soc.134(22),9138–9141 (2012).
  Medline CASGoogle Scholar
• 35  Betzi S, Alam R, Martin M et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol.6(5),492–501 (2011).
  Medline CASGoogle Scholar
• 36  Martin MP, Alam R, Betzi S, Ingles DJ, Zhu JY, Schonbrunn E. A novel approach to the discovery of small-molecule ligands of CDK2. ChemBioChem13(14),2128–2136 (2012).
  Medline CASGoogle Scholar
• 37  Jahnke W, Grotzfeld RM, Pelle X et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J. Am. Chem. Soc.132(20),7043–7048 (2010).
  Medline CASGoogle Scholar
• 38  Hardy JA, Wells JA. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol.14(6),706–715 (2004).
  Medline CASGoogle Scholar
• 39  Erlanson DA, Ballinger MD, Wells JA. Tethering. Methods Princ. Med. Chem.34,285–310 (2006).
  CASGoogle Scholar
• 40  Dennis MS, Eigenbrot C, Skelton NJ et al. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature404,465–470 (2000).
  Medline CASGoogle Scholar
• 41  Navratilova I, Macdonald G, Robinson C et al. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action. J. Biomol. Screen.17(2),183–193 (2012).
  Medline CASGoogle Scholar
• 42  Comess KM, Sun C, Abad-Zapatero C et al. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem. Biol.6(3),234–244 (2011).
  Medline CASGoogle Scholar
• 43  Ashwell MA, Lapierre JM, Brassard C et al. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J. Med. Chem.55(11),5291–5310 (2012).
  Medline CASGoogle Scholar
• 44  Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res.64(18),6652–6659 (2004).
  Medline CASGoogle Scholar
• 45  Stockman BJ, Kothe M, Kohls D et al. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem. Biol. Drug Design73(2),179–188 (2009).
  Medline CASGoogle Scholar
• 46  Kumar A, Voet A, Zhang KYJ. Fragment based drug design: from experimental to computational approaches. Curr. Med. Chem.19,5128–5147 (2012).
  Medline CASGoogle Scholar
• 47  Jahnke W, Perez LB, Paris CG, Strauss A, Fendrich G, Nalin CM. Second-site NMRr screening with a spin-labeled first ligand. J. Am. Chem. Soc.122,7394–7395 (2000).
  CASGoogle Scholar
• 48  Jahnke W, Blommers MJJ, Fernandez C, Zwingelstein C, Amstutz R. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. ChemBioChem6,1607–1610 (2005).
  Medline CASGoogle Scholar
• 49  McCoy MA, Senior MM, Wyss DF. Screening of protein kinases by ATP-STD NMR spectroscopy. J. Am. Chem. Soc.127(22),7978–7979 (2005).
  Medline CASGoogle Scholar
• 50  Vazquez J, De SK, Chen L-H et al. Development of paramagnetic probes for molecular recognition studies in protein kinases. J. Med. Chem.51,3460–3465 (2008).
  Medline CASGoogle Scholar
• 51  Moy FJ, Lee A, Gavrin LK et al. Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance. J.Med. Chem.53,1238–1249 (2010).
  CASGoogle Scholar
• 52  Stebbins JL, De SK, Machleidt T et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl Acad. Sci. USA.105,16809–16813 (2008).
  Medline CASGoogle Scholar
• 53  Engel M, Hindie V, Lopez-Garcia LA et al. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J.25(23),5469–5480 (2006).▪ One of the first descriptions of an allosteric activator.
  Medline CASGoogle Scholar
• 54  Wei L, Gao X, Warne R et al. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Bioorg. Med. Chem. Lett.20(13),3897–3902 (2010).
  Medline CASGoogle Scholar
• 55  Wilhelm A, Lopez-Garcia LA, Busschots K et al. 2-(3-oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept. J. Med. Chem.55,9817–9830 (2012).
  Medline CASGoogle Scholar
• 56  Frohner W, Lopez-Garcia LA, Neimanis S et al. 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCzeta. J. Med. Chem.54(19),6714–6723 (2011).
  MedlineGoogle Scholar
• 57  Lopez-Garcia LA, Schulze JO, Frohner W et al. Allosteric regulation of protein kinase PKCzeta by the N-terminal C1 domain and small compounds to the PIF-pocket. Chem. Biol.18(11),1463–1473 (2011).
  Medline CASGoogle Scholar
• 58  Nagar B, Hantschel O, Young MA et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell112(6),859–871 (2003).
  Medline CASGoogle Scholar
• 59  Cowan-Jacob SW, Fendrich G, Manley PW et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure13(6),861–871 (2005).
  Medline CASGoogle Scholar
• 60  Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE. How does a drug molecule find its target binding site? J. Am. Chem. Soc.133(24),9181–9183 (2011).
  Medline CASGoogle Scholar
• 61  Palomo V, Soteras I, Perez DI et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J. Med. Chem.54(24),8461–8470 (2011).
  Medline CASGoogle Scholar
• 62  Huang Z, Mou L, Shen Q et al. ASD v2.0: updated content and novel features focusing on allosteric regulation. Nucleic acids Res.42(1),D510–D516 (2013).
  MedlineGoogle Scholar
• 63  Huang W, Lu S, Huang Z et al. Allosite: a method for predicting allosteric sites. Bioinformatics29(18),2357–2359 (2013).
  Medline CASGoogle Scholar
• 64  Panjkovich A, Daura X. Exploiting protein flexibility to predict the location of allosteric sites. BMC Bioinform.13,273 (2012).
  MedlineGoogle Scholar
• 65  Li Y, Liang J, Siu T et al. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity. Bioorg. Med. Chem. Lett.19(3),834–836 (2009).
  Medline CASGoogle Scholar
• 66  Zhao Z, Robinson RG, Barnett SF et al. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg. Med. Chem. Lett.18(1),49–53 (2008).
  MedlineGoogle Scholar
• 67  Converso A, Hartingh T, Garbaccio RM et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett.19(4),1240–1244 (2009).
  Medline CASGoogle Scholar
• 68  Chen F, Hancock CN, Macias AT et al. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg. Med. Chem. Lett.16(24),6281–6287 (2006).
  Medline CASGoogle Scholar
• 69  Hatzivassiliou G, Haling JR, Chen H et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature501(7466),232–236 (2013).
  Medline CASGoogle Scholar
• 70  Yap TA, Yan L, Patnaik A et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol.29,4688–4695 (2011).
  Medline CASGoogle Scholar
• 71  Perry JJ, Harris RM, Moiani D, Olson AJ, Tainer JA. p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. J. Mol. Biol.391(1),1–11 (2009).
  Medline CASGoogle Scholar
• 72  Rusconi P, Caiola E, Broggini M. RAS/RAF/MEK inhibitors in oncology. Curr. Med. Chem.19(8),1164–1176 (2012).
  Medline CASGoogle Scholar
• 73  Simpson GL, Hughes JA, Washio Y, Bertrand SM. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. Curr. Opin. Drug Discov. Devel.12(5),585–596 (2009).
  Medline CASGoogle Scholar
• 74  Eglen R, Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol. Ther.130(2),144–156 (2011).
  Medline CASGoogle Scholar
• 75  Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs19(11),1355–1366 (2010).
  Medline CASGoogle Scholar
• 76  Yang J, Campobasso N, Biju MP et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol.18(2),177–186 (2011).
  Medline CASGoogle Scholar
• 77  Raina D, Pandey P, Ahmad R et al. c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. J. Biol. Chem.280(12),11147–11151 (2005).
  Medline CASGoogle Scholar
• 78  Caracciolo D, Valtieri M, Venturelli D, Peschle C, Gewirtz AM, Calabretta B. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science245(4922),1107–1110 (1989).
  Medline CASGoogle Scholar
• 79  Rosti V, Bergamaschi G, Lucotti C et al. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood86(9),3387–3393 (1995).
  Medline CASGoogle Scholar
• 80  Allington TM, Galliher-Beckley AJ, Schiemann WP. Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J.23(12),4231–4243 (2009).
  Medline CASGoogle Scholar
• 81  Hindie V, Stroba A, Zhang H et al. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Biol.5(10),758–764 (2009).
  Medline CASGoogle Scholar
• 82  Busschots K, Lopez-Garcia LA, Lammi C et al. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol.19(9),1152–1163 (2012).
  Medline CASGoogle Scholar
• 83  Bobkova EV, Weber MJ, Xu Z et al. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J. Biol. Chem.285(24),18838–18846 (2010).
  Medline CASGoogle Scholar
• 84  Li S, Covino ND, Stein EG, Till JH, Hubbard SR. Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor. J. Biol. Chem.278(28),26007–26014 (2003).
  Medline CASGoogle Scholar
• 85  Liu K, Xu L, Szalkowski D et al. Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. J. Med. Chem.43(19),3487–3494 (2000).
  Medline CASGoogle Scholar
• 86  Lee KH, Hsu EC, Guh JH et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) Activator. J. Biol. Chem.286(45),39247–39258 (2011).
  Medline CASGoogle Scholar
• 87  Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin. Investig. Drugs21(8),1155–1167 (2012).
  Medline CASGoogle Scholar
• 88  Giordanetto F, Karis D. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature. Expert Opin. Ther. Pat.22(12),1467–1477 (2012).
  Medline CASGoogle Scholar
• 89  Lipinski CA, Stam JG, Pereira JN, Ackerman NR, Hess HJ. Bronchodilator and antiulcer phenoxypyrimidinones. J. Med. Chem.23(9),1026–1031 (1980).
  Medline CASGoogle Scholar
• 90  Saporito MS, Ochman AR, Lipinski CA, Handler JA, Reaume AG. MLR-1023 is a potent and selective allosteric activator of LYN kinase in vitro that improves glucose tolerance in vivo. J. Pharmacol. Exp. Ther.342(1),15–22 (2012).
  Medline CASGoogle Scholar
• 91  Muller G, Wied S, Frick W. Cross talk of pp125(FAK) and pp59(LYN) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes. Mol. Cell. Biol.20(13),4708–4723 (2000).
  Medline CASGoogle Scholar
• 92  Massa SM, Yang T, Xie Y et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest.120(5),1774–1785 (2010).
  Medline CASGoogle Scholar
• 93  Fedorov O, Muller S, Knapp S. The (un)targeted cancer kinome. Nat. Chem. Biol.6(3),166–169 (2010).
  Medline CASGoogle Scholar
• 94  Fedorov O, Huber K, Eisenreich A et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol.18(1),67–76 (2011).
  Medline CASGoogle Scholar
• 95  Debdab M, Carreaux F, Renault S et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. modulation of alternative pre-RNA splicing. J. Med. Chem.54(12),4172–4186 (2011).
  Medline CASGoogle Scholar
• 96  Gammons MV, Fedorov O, Ivison D et al. Topical Antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol. Vis. Sci.54(9),6052–6062 (2013).
  Medline CASGoogle Scholar
• 97  Rosenthal AS, Tanega C, Shen M et al. An inhibitor of the Cdc2-like kinase 4 (Clk4). In: Probe Reports from the NIH Molecular Libraries Program. MD, USA (2010).
  Google Scholar
• 98  Dudkiewicz M, Szczepinska T, Grynberg M, Pawlowski K. A novel protein kinase-like domain in a selenoprotein, widespread in the tree of life. PLoS ONE7(2),e32138 (2012).
  Medline CASGoogle Scholar
• 99  Koike T, Izumikawa T, Tamura J, Kitagawa H. FAM20B is a kinase that phosphorylates xylose in the glycosaminoglycan-protein linkage region. Biochem. J.421(2),157–162 (2009).
  Medline CASGoogle Scholar
• 100  Ishikawa HO, Takeuchi H, Haltiwanger RS, Irvine KD. Four-jointed is a Golgi kinase that phosphorylates a subset of cadherin domains. Science321(5887),401–404 (2008).
  Medline CASGoogle Scholar
• 101  Ishikawa HO, Xu A, Ogura E, Manning G, Irvine KD. The Raine syndrome protein FAM20C is a Golgi kinase that phosphorylates bio-mineralization proteins. PLoS ONE7(8),e42988 (2012).
  Medline CASGoogle Scholar
• 102  Tagliabracci VS, Engel JL, Wen J et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science336(6085),1150–1153 (2012).▪ First example of a secreted novel kinase.
  Medline CASGoogle Scholar
• 103  Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol.19(8),754–759 (2012).▪ First structural insight into the pseudokinase domain of JAK2.
  Medline CASGoogle Scholar
• 104  Mukherjee K, Sharma M, Urlaub H et al. CASK Functions as a Mg²⁺-independent neurexin kinase. Cell133(2),328–339 (2008).
  Medline CASGoogle Scholar
• 105  Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure17(1),128–138 (2009).
  Medline CASGoogle Scholar
• 106  Barr AJ, Ugochukwu E, Lee WH et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell136(2),352–363 (2009).
  Medline CASGoogle Scholar
• 107  Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell. Biol.16(9),443–452 (2006).
  Medline CASGoogle Scholar
• 108  Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem.275(22),16795–16801 (2000).
  Medline CASGoogle Scholar
• 109  Min X, Lee BH, Cobb MH, Goldsmith EJ. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure12(7),1303–1311 (2004).
  Medline CASGoogle Scholar
• 110  Yagi YI, Abe K, Ikebukuro K, Sode K. Kinetic mechanism and inhibitor characterization of WNK1 kinase. Biochemistry48(43),10255–10266 (2009).
  Medline CASGoogle Scholar
• 111  Abe Y, Matsumoto S, Wei S et al. Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J. Biol. Chem.276(47),44003–44011 (2001).
  Medline CASGoogle Scholar
• 112  Adams JA, Taylor SS. Divalent metal ions influence catalysis and active-site accessibility in the cAMP-dependent protein kinase. Protein Sci.2(12),2177–2186 (1993).
  Medline CASGoogle Scholar
• 113  Waas WF, Dalby KN. Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2. Biochemistry42(10),2960–2970 (2003).
  Medline CASGoogle Scholar
• 114  Saitsu H, Kato M, Osaka H et al. CASK aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. Epilepsia53(8),1441–1449 (2012).
  Medline CASGoogle Scholar
• 115  Takanashi J, Okamoto N, Yamamoto Y et al. Clinical and radiological features of Japanese patients with a severe phenotype due to CASK mutations. Am. J. Med. Genet. A158A(12),3112–3118 (2012).
  MedlineGoogle Scholar
• 116  Moog U, Kutsche K, Kortum F et al. Phenotypic spectrum associated with CASK loss-of-function mutations. J. Med. Genet.48(11),741–751 (2011).
  Medline CASGoogle Scholar
• 117  Tarpey PS, Smith R, Pleasance E et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat. Genet.41(5),535–543 (2009).
  Medline CASGoogle Scholar
• 118  Piluso G, D’amico F, Saccone V et al. A missense mutation in CASK causes FG syndrome in an Italian family. Am. J. Hum. Genet.84(2),162–177 (2009).
  Medline CASGoogle Scholar
• 119  Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl Acad. Sci. USA106(51),21608–21613 (2009).
  Medline CASGoogle Scholar
• 120  Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA107(17),7692–7697 (2010).
  Medline CASGoogle Scholar
• 121  Jaiswal BS, Kljavin NM, Stawiski EW et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell23(5),603–617 (2013).
  Medline CASGoogle Scholar
• 122  Zeqiraj E, Van Aalten DM. Pseudokinases-remnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol.20(6),772–781 (2010).
  Medline CASGoogle Scholar
• 123  Qin J, Wu C. ILK: a pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr. Opin. Cell. Biol.24(5),607–613 (2012).
  Medline CASGoogle Scholar
• 124  Akhtar N, Streuli CH. An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium. Nat. Cell. Biol.15(1),17–27 (2013).
  Medline CASGoogle Scholar
• 125  McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase--essential roles in physiology and cancer biology. J. Cell. Sci.121(Pt 19),3121–3132 (2008).
  Medline CASGoogle Scholar
• 126  Xing Y, Qi J, Deng S, Wang C, Zhang L, Chen J. Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition. Exp. Cell. Res.319(13),2058–2072 (2013).
  Medline CASGoogle Scholar
• 127  Li R, Liu B, Yin H, Sun W, Yin J, Su Q. Overexpression of integrin-linked kinase (ILK) is associated with tumor progression and an unfavorable prognosis in patients with colorectal cancer. J. Mol. Histol.44(2),183–189 (2013).
  Medline CASGoogle Scholar
• 128  Li J, Yang ZL, Ren X et al. ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol.34(1),359–368 (2013).
  Medline CASGoogle Scholar
• 129  Choi YP, Kim BG, Gao MQ, Kang S, Cho NH. Targeting ILK and beta4 integrin abrogates the invasive potential of ovarian cancer. Biochem. Biophys. Res. Commun.427(3),642–648 (2012).
  Medline CASGoogle Scholar
• 130  Fukuda K, Gupta S, Chen K, Wu C, Qin J. The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol. Cell.36(5),819–830 (2009).
  Medline CASGoogle Scholar
• 131  Ekambaram R, Enkvist E, Vaasa A et al. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. ChemMedChem8(6),909–913 (2013).
  Medline CASGoogle Scholar
• 132  Lavogina D, Enkvist E, Uri A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem5(1),23–34 (2010).
  Medline CASGoogle Scholar
• 133  Rorth P, Szabo K, Texido G. The level of C/EBP protein is critical for cell migration during Drosophila oogenesis and is tightly controlled by regulated degradation. Mol. Cell.6(1),23–30 (2000).
  Medline CASGoogle Scholar
• 134  Yoshida A, Kato JY, Nakamae I, Yoneda-Kato N. COP1 targets C/EBPalpha for degradation and induces acute myeloid leukemia via Trib1. Blood122(10),1750–1760 (2013).
  Medline CASGoogle Scholar
• 135  Liang KL, Rishi L, Keeshan K. Tribbles in acute leukemia. Blood121(21),4265–4270 (2013).
  Medline CASGoogle Scholar
• 136  Satoh T, Kidoya H, Naito H et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature495(7442),524–528 (2013).
  Medline CASGoogle Scholar
• 137  Mancini E, Sanjuan-Pla A, Luciani L et al. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J.31(2),351–365 (2012).
  Medline CASGoogle Scholar
• 138  Dedhia PH, Keeshan K, Uljon S et al. Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia. Blood116(8),1321–1328 (2010).
  Medline CASGoogle Scholar
• 139  Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood116(15),2768–2775 (2010).
  Medline CASGoogle Scholar
• 140  Yokoyama T, Toki T, Aoki Y et al. Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. Blood119(11),2608–2611 (2012).
  Medline CASGoogle Scholar
• 141  Bowers AJ, Scully S, Boylan JF. SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia. Oncogene22(18),2823–2835 (2003).
  Medline CASGoogle Scholar
• 142  Keeshan K, Bailis W, Dedhia PH et al. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood116(23),4948–4957 (2010).
  Medline CASGoogle Scholar
• 143  Toms AV, Deshpande A, McNally R et al. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol.20(10),1221–1223 (2013).▪ First structural insight into the pseudokinase domain of JAK1 and its role regulating JAK kinase activity.
  Medline CASGoogle Scholar
• 144  Silvennoinen O, Ungureanu D, Niranjan Y, Hammaren H, Bandaranayake R, Hubbard SR. New insights into the structure and function of the pseudokinase domain in JAK2. Biochem. Soc. Trans.41(4),1002–1007 (2013).
  Medline CASGoogle Scholar
• 145  Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS ONE5(6),e11157 (2010).
  MedlineGoogle Scholar
• 146  Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature470(7333),163–165 (2011).
  Medline CASGoogle Scholar
• 147  Gill AL, Frederickson M, Cleasby A et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem.48(2),414–426 (2005).
  Medline CASGoogle Scholar
• 148  Moffett K, Konteatis Z, Nguyen D et al. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). Bioorg. Med. Chem. Lett.21(23),7155–7165 (2011).
  Medline CASGoogle Scholar
• 149  Bukhtiyarova M, Karpusas M, Northrop K, Namboodiri HVM, Springman EB. Mutagenesis of p38α MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state. Biochemistry46,5687–5696 (2007).
  Medline CASGoogle Scholar
• 150  Kluter S, Grutter C, Naqvi T et al. Displacement assay for the detection of stabilizers of inactive kinase conformations. J. Med. Chem.53(1),357–367 (2010).
  MedlineGoogle Scholar
• 151  Ahn YM, Clare M, Ensinger CL et al. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorg. Med. Chem. Lett.20(19),5793–5798 (2010).
  Medline CASGoogle Scholar
• 152  Over B, Wetzel S, Grutter C et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat. Chem.5(1),21–28 (2013).
  Medline CASGoogle Scholar
• 153  Tecle H, Feru F, Liu H et al. The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay. Chem. Biol. Drug Design74(6),547–559 (2009).
  Medline CASGoogle Scholar
• 154  Tzarum N, Eisenberg-Domovich Y, Gills JJ, Dennis PA, Livnah O. Lipid molecules induce p38alpha activation via a novel molecular switch. J. Mol. Biol.424(5),339–353 (2012).
  Medline CASGoogle Scholar
• 155  Warmus JS, Flamme C, Zhang LY et al. 2-alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase). Bioorg. Med. Chem. Lett.18(23),6171–6174 (2008).
  Medline CASGoogle Scholar
• 156  Fischmann TO, Smith CK, Mayhood TW et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry48(12),2661–2674 (2009).
  Medline CASGoogle Scholar
• 157  Iverson C, Larson G, Lai C et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res.69(17),6839–6847 (2009).
  Medline CASGoogle Scholar
• 158  Wallace MB, Adams ME, Kanouni T et al. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors. Bioorg. Med. Chem. Lett.20(14),4156–4158 (2010).
  Medline CASGoogle Scholar
• 159  Isshiki Y, Kohchi Y, Iikura H et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg. Med. Chem. Lett.21(6),1795–1801 (2011).
  Medline CASGoogle Scholar
• 160  Dong Q, Dougan DR, Gong X et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg. Med. Chem. Lett.21(5),1315–1319 (2011).
  Medline CASGoogle Scholar
• 161  Rice KD, Aay N, Anand NK et al. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med. Chem. Lett.3,416–421 (2012).
  Medline CASGoogle Scholar
• 162  Meier C, Brookings DC, Ceska TA et al. Engineering human MEK-1 for structural studies: a case study of combinatorial domain hunting. J. Struct. Biol.177(2),329–334 (2012).
  Medline CASGoogle Scholar
• 163  Heald RA, Jackson P, Savy P et al. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. J. Med. Chem.55,4594–4604 (2012).
  Medline CASGoogle Scholar
• 164  Hartung IV, Hitchcock M, Puhler F et al. Optimization of allosteric MEK inhibitors. Part 1: venturing into underexplored SAR territories. Bioorg. Med. Chem. Lett.23(8),2384–2390 (2013).
  Medline CASGoogle Scholar
• 165  Sadowsky JD, Burlingame MA, Wolan DW, McClendon CL, Jacobson MP, Wells JA. Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl Acad. Sci. USA108(15),6056–6061 (2011).
  Medline CASGoogle Scholar
• 166  Gilsbach BK, Ho FY, Vetter IR, Van Haastert PJ, Wittinghofer A, Kortholt A. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc. Natl Acad. Sci. USA109(26),10322–10327 (2012).
  Medline CASGoogle Scholar
• 167  Fujino A, Fukushima K, Namiki N, Kosugi T, Takimoto-Kamimura M. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Acta Crystallogr. D Biol. Crystallogr.66(Pt 1),80–87 (2010).
  Medline CASGoogle Scholar
• 168  Chan WW, Wise SC, Kaufman MD et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell19(4),556–568 (2011).
  Medline CASGoogle Scholar
• 169  Salah E, Ugochukwu E, Barr AJ, Von DF, Knapp S, Elkins JM. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J. Med. Chem.54,2359–2367 (2011).
  Medline CASGoogle Scholar
• 170  Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GP, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS ONE5(9),e12913 (2010).
  MedlineGoogle Scholar
• 171  Schneider EV, Boettcher J, Huber R, Maskos K, Neumann L. Structure–kinetic relationship study of CDK8/CycC specific compounds. Proc. Natl Acad. Sci. USA110,8081–8086 (2013).
  Medline CASGoogle Scholar
• 172  Bhattacharya SK, Aspnes GE, Bagley SW et al. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. Bioorg. Med. Chem. Lett.22(24),7523–7529 (2012).
  Medline CASGoogle Scholar
• 173  Xie T, Peng W, Liu Y et al. Structural basis of RIP1 inhibition by necrostatins. Structure21(3),493–499 (2013).
  Medline CASGoogle Scholar
• 174  Eswaran J, Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim. Biophys. Acta1804(3),429–432 (2010).
  Medline CASGoogle Scholar